(Q46028265)

English

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

scientific article published on 4 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

methylprednisolone

1 reference

based on heuristic

inferred from title

Kjell-Morten Myhr

7

object named as

Kjell-Morten Myhr

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Anders Svenningsson

3

object named as

Anders Svenningsson

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Per Soelberg Sørensen

1

object named as

Per Soelberg Sorensen

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Svein Ivar Mellgren

2

object named as

Svein Ivar Mellgren

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Lise Vejby Søgaard

8

object named as

Lise Vejby Søgaard

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

author name string

Irina Elovaara

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Jette Lautrup Frederiksen

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Antonie Giaever Beiske

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Inge Christoffer Olsen

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Magnhild Sandberg-Wollheim

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

publication date

4 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

519-529

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrarater and interrater reliability of the MS functional composite outcome measure.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in functional and structural MR image analysis and implementation as FSL

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid glucocorticoid effects on immune cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucocorticoids in T cell development and function*.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Corticosteroid treatment of optic neuritis: a need to change treatment practices. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970085-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(09)70085-7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19409854

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46028265&oldid=1575946691"